000170010 001__ 170010
000170010 005__ 20260316092629.0
000170010 0247_ $$2doi$$a10.3389/fendo.2024.1498726
000170010 0248_ $$2sideral$$a148528
000170010 037__ $$aART-2024-148528
000170010 041__ $$aeng
000170010 100__ $$aCorripio, Raquel
000170010 245__ $$aAdult height in girls with idiopathic central precocious puberty treated with triptorelin
000170010 260__ $$c2024
000170010 5060_ $$aAccess copy available to the general public$$fUnrestricted
000170010 5203_ $$aObjective: Idiopathic central precocious puberty (CPP) precipitates epiphyseal fusion of growth plates in long bones, leading to reduced adult stature. Gonadotropin-releasing hormone analogues (GnRHa) are the treatment of choice for idiopathic CPP, but their benefit on height gain is unclear. We aimed to elucidate the effects of GnRHa treatment on adult height in girls with idiopathic CPP.
Design: This prospective observational descriptive study analyzed data of girls with idiopathic CPP diagnosed at 55 centers in Spain between January 1, 1998 and December 31, 2012 included in the Spanish Society for Pediatric Endocrinology’s national registry.
Methods: We included girls with idiopathic CPP (thelarche < 8 years, positive LHRH stimulation test, bone age > 1 year older than chronological age, and normal brain imaging) treated with triptorelin (3.75 mg monthly, adjusted according to LHRH test results and clinical findings). We assessed weight, height, BMI, and secondary sexual characteristics every 6 months and bone age every 12 months until adult height (AH) was attained. The primary outcome was the difference between AH and target height (TH).
Results: A total of 465 girls (18.90% adopted) were included; we analyzed data recorded at treatment end in 358 girls and at AH in 216. Mean difference between AH and TH was -1.5 (95%CI: -2.56− -0.45) cm and between AH and PAH 2,57 (95%CI:-3.56− -1.58) cm.
Conclusions_ GnRHa treatment helps preserve genetic growth potential in girls with idiopathic CPP.
000170010 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000170010 590__ $$a4.6$$b2024
000170010 591__ $$aENDOCRINOLOGY & METABOLISM$$b43 / 193 = 0.223$$c2024$$dQ1$$eT1
000170010 592__ $$a1.472$$b2024
000170010 593__ $$aEndocrinology, Diabetes and Metabolism$$c2024$$dQ1
000170010 594__ $$a7.4$$b2024
000170010 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000170010 700__ $$aSoriano-Guillén, Leandro
000170010 700__ $$aHerrero, Francisco-Javier
000170010 700__ $$aCastro-Feijoó, Lidia
000170010 700__ $$aEscribano, Aránzazu
000170010 700__ $$aSol-Ventura, Paula
000170010 700__ $$aEspino, Rafael
000170010 700__ $$aVela, Amaia
000170010 700__ $$0(orcid)0000-0003-2832-2266$$aLabarta, José-Ignacio$$uUniversidad de Zaragoza
000170010 700__ $$aArgente, Jesús
000170010 7102_ $$11011$$2670$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Pediatría
000170010 773__ $$g15 (2024), 1498726 [9 pp.]$$pFront. endocrinol.$$tFrontiers in Endocrinology$$x1664-2392
000170010 8564_ $$s998582$$uhttps://zaguan.unizar.es/record/170010/files/texto_completo.pdf$$yVersión publicada
000170010 8564_ $$s2190354$$uhttps://zaguan.unizar.es/record/170010/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000170010 909CO $$ooai:zaguan.unizar.es:170010$$particulos$$pdriver
000170010 951__ $$a2026-03-16-08:16:46
000170010 980__ $$aARTICLE